Injectable PNP Hydrogels for Sustained Immunomodulator Co-Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccine and immunotherapy delivery methods fail to provide sustained exposure of immunomodulatory components to the immune system, leading to inadequate immune responses due to inappropriate temporal control over antigen presentation and adjuvant activation, especially when multiple compounds of varying sizes and chemical natures are involved.
Innovation Solution
An injectable self-healing polymer-nanoparticle hydrogel (PNP) platform that encapsulates immunomodulatory cargos, allowing for tunable release over days to weeks, enhancing immune response by creating a local inflammatory niche and promoting germinal center responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If subunit vaccines are used to drive highly specific antigen targeting, then safety challenges are reduced, but the ability to produce robust and persistent immune responses is limited
Solution Approach 1:
The hydrogel enables continuous and sustained release of the antigen over an extended period, transforming the single bolus administration into prolonged temporal exposure. This continuous action allows the immune system to receive antigenic stimulation over days to weeks, mimicking natural infection kinetics and thereby generating robust and persistent immune responses without the safety issues of whole pathogen vaccines
Solution Approach 2:
The hydrogel system provides dynamic control over antigen release kinetics, allowing the material to adapt the release rate based on immune system response and cargo properties. This dynamic temporal control enables optimization of immune response generation by adjusting the duration and rate of antigen presentation, transforming static vaccine formulations into dynamically responsive delivery systems
2Adaptability or versatility
If multiple compounds of varying sizes and chemical natures are combined for co-release, then comprehensive immune activation is achieved, but proper timing becomes extremely challenging or impossible
Solution Approach 1:
The hydrogel acts as a temporal mediator that synchronizes the release of multiple compounds with different molecular sizes and chemical properties. By incorporating all compounds into the single hydrogel matrix, the system eliminates the timing coordination problems that would arise from separate administrations, allowing comprehensive immune activation through controlled co-release
Solution Approach 2:
The hydrogel system controls the release parameters of multiple compounds by adjusting the gel's physical and chemical properties, such as mesh size, degradation rate, and diffusion characteristics. This parameter control enables different compounds to be released at appropriate rates and times relative to each other, maintaining proper timing even for molecules of varying sizes and chemistries
3Duration of action of moving object
If polymer microparticles are used for prolonged vaccine delivery, then sustained exposure is achieved, but organic solvents are required for synthesis that can denature biologic cargo
Solution Approach 1:
The hydrogel system changes the synthesis parameters from traditional organic solvent-based methods to aqueous or physically crosslinked formulations. This parameter change eliminates the need for organic solvents during synthesis, thereby preventing denaturation of biologic cargo while still achieving prolonged delivery duration through the hydrogel's controlled degradation and diffusion mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PNP hydrogel platform enhances humoral immune responses by prolonging antigen exposure, leading to higher affinity antibody production and humoral immune memory, effectively delivering multiple compounds with varying sizes and chemical properties.
Implementation Method 1
A ratio of a diffusivity of the first immunomodulatory cargo through the hydrogel to a diffusivity of the second immunomodulatory cargo through the hydrogel is less than 3
Implementation Method 2
The hydrogel includes a polymer non-covalently crossed-linked with a plurality of nanoparticles
Data Source
AI summary
An immunomodulatory delivery system includes a hydrogel, a first immunomodulatory cargo encapsulated in the cargo, and a second immunomodulatory cargo encapsulated in the hydrogel. The hydrogel includes a polymer non-covalently crossed-linked with a plurality of nanoparticles. The first immunomodulatory cargo is smaller than the second immunomodulatory cargo. A ratio of a diffusivity of the first immunomodulatory cargo through the hydrogel to a diffusivity of the second immunomodulatory cargo through the hydrogel is less than 3.